Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02279160 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02279160 is a Phase 2 study that has completed, run by United Therapeutics. The registered enrollment target is 61 participants.
The verdict
NCT02279160, a Phase 2 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label extension study, APD811-007. A total of 61 patients with PAH were enrolled.
Interventions
- DRUG Placebo
- DRUG APD811
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02279160
The ClinicalTrials.gov registry entry for NCT02279160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02279160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02279160 about?
NCT02279160 is a clinical study titled "Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension". The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label extension study, APD811-007. A total of 61 patients with PAH were enro...
What is the current status of trial NCT02279160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2014-12. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02279160?
The interventions under investigation include: Placebo (DRUG), APD811 (DRUG).
Who is sponsoring clinical trial NCT02279160?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.